Top

Current Hematologic Malignancy Reports

Published in:

01-12-2018 | CART and Immunotherapy (M Ruella, Section Editor)

Novel Immunotherapies for T Cell Lymphoma and Leukemia

Authors: Paola Ghione, Alison J. Moskowitz, Nadia E. K. De Paola, Steven M. Horwitz, Marco Ruella

Published in: Current Hematologic Malignancy Reports | Issue 6/2018

Abstract

Purpose of Review

Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are characterized by poor clinical outcomes. This review describes the rational and preliminary results of immunotherapy for patients with T cell lymphoma and leukemia.

Recent Findings

For T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity. One of the major hurdles to targeting T cell neoplasms is that activation or elimination of T cells, either normal or neoplastic, can cause significant toxicity. A need to develop novel safe and effective immunotherapies for T cell neoplasms exists.

Summary

In this review, we will discuss the rationale for immunotherapy of T cell leukemia and lymphoma and present the most recent therapeutic approaches.

June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5. https://doi.org/10.1126/science.aar6711.CrossRefPubMed

Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366(21):2008–16. https://doi.org/10.1056/NEJMct1114348.CrossRefPubMed

Brody J, Kohrt H, Marabelle A, Levy R. Active and passive immunotherapy for lymphoma: proving principles and improving results. J Clin Oncol. 2011;29(14):1864–75. https://doi.org/10.1200/jco.2010.33.4623.CrossRefPubMed

Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68–83. https://doi.org/10.1182/blood-2017-07-740993.CrossRefPubMedPubMedCentral

Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, et al. NCCN guidelines insights: T-cell lymphomas, version 2.2018. J Natl Compr Cancer Netw. 2018;16(2):123–35. https://doi.org/10.6004/jnccn.2018.0007.CrossRef

Mehta-Shah N, Ratner L, Horwitz SM. Adult T-cell leukemia/lymphoma. J Oncol Pract. 2017;13(8):487–92. https://doi.org/10.1200/jop.2017.021907.CrossRefPubMedPubMedCentral

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89(11):3909–18.

Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30. https://doi.org/10.1200/jco.2008.16.4558.CrossRefPubMed

Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Investig. 2007;117(3):823–34. https://doi.org/10.1172/jci26833.CrossRefPubMedPubMedCentral

10.

Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res. 2007;67(22):10703–10. https://doi.org/10.1158/0008-5472.can-07-1708.CrossRefPubMed

11.

Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–59. https://doi.org/10.3322/caac.21357.CrossRefPubMed

12.

Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113(17):3931–7. https://doi.org/10.1182/blood-2008-10-185256.CrossRefPubMed

13.

Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78(12):3269–74.PubMed

14.

Drobna M, Szarzynska-Zawadzka B, Dawidowska M. T-cell acute lymphoblastic leukemia from miRNA perspective: basic concepts, experimental approaches, and potential biomarkers. Blood Rev. 2018. https://doi.org/10.1016/j.blre.2018.04.003.

15.

Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016;16(8):494–507. https://doi.org/10.1038/nrc.2016.63.CrossRefPubMed

16.

Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, et al. The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-cell project. Haematologica. 2018;103:1191–7. https://doi.org/10.3324/haematol.2017.186577.CrossRefPubMedPubMedCentral

17.

Murray D, Eldershaw SA, Pearce H, Davies N, McMurray J, Scarisbrick JJ, et al. T cell versus T cell; a study of the immune checkpoint landscape in cutaneous T cell lymphoma. Blood. 2754;130(Suppl 1):2017.

18.

Miyatake Y, Oliveira AL, Jarboui MA, Ota S, Tomaru U, Teshima T, et al. Protective roles of epithelial cells in the survival of adult T-cell leukemia/lymphoma cells. Am J Pathol. 2013;182(5):1832–42. https://doi.org/10.1016/j.ajpath.2013.01.015.CrossRefPubMed

19.

Kinpara S, Hasegawa A, Utsunomiya A, Nishitsuji H, Furukawa H, Masuda T, et al. Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J Virol. 2009;83(10):5101–8. https://doi.org/10.1128/jvi.02564-08.CrossRefPubMedPubMedCentral

20.

Vicario M, Mattiolo A, Montini B, Piano MA, Cavallari I, Amadori A, et al. A preclinical model for the ATLL lymphoma subtype with insights into the role of microenvironment in HTLV-1-mediated lymphomagenesis. Front Microbiol. 2018;9:1215. https://doi.org/10.3389/fmicb.2018.01215.CrossRefPubMedPubMedCentral

21.

Thumann P, Luftl M, Moc I, Bagot M, Bensussan A, Schuler G, et al. Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy. Br J Dermatol. 2003;149(6):1128–42.CrossRefPubMed

22.

Miyagaki T, Sugaya M, Fujita H, Ohmatsu H, Kakinuma T, Kadono T, et al. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Investig Dermatol. 2010;130(9):2304–11. https://doi.org/10.1038/jid.2010.128.CrossRefPubMed

23.

Rubio Gonzalez B, Zain J, Rosen ST, Querfeld C. Tumor microenvironment in mycosis fungoides and Sezary syndrome. Curr Opin Oncol. 2016;28(1):88–96. https://doi.org/10.1097/cco.0000000000000243.CrossRefPubMed

24.

Querfeld C, Curran SA, Leung S, Myskowski PL, Horwitz SM, Halpern AC, et al. T cells in CTCL have an exhausted phenotype while cutaneous dendritic cells display a normally activated mature phenotype. Blood. 2014;124(21):1695.

25.

Russ A, Hua AB, Montfort WR, Rahman B, Riaz IB, Khalid MU, et al. Blocking “don’t eat me” signal of CD47-SIRPalpha in hematological malignancies, an in-depth review. Blood Rev. 2018. https://doi.org/10.1016/j.blre.2018.04.005.

26.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The N Engl J Med. 2012;366(26):2455–65. https://doi.org/10.1056/NEJMoa1200694.CrossRefPubMed

27.

Kulpa DA, Lawani M, Cooper A, Peretz Y, Ahlers J, Sekaly RP. PD-1 coinhibitory signals: the link between pathogenesis and protection. Semin Immunol. 2013;25(3):219–27. https://doi.org/10.1016/j.smim.2013.02.002.CrossRefPubMed

28.

Ruella M, Kalos M. Adoptive immunotherapy for cancer. Immunol Rev. 2014;257(1):14–38. https://doi.org/10.1111/imr.12136.CrossRefPubMed

29.

Sugaya M, Miyagaki T, Ohmatsu H, Suga H, Kai H, Kamata M, et al. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci. 2012;68(1):45–51. https://doi.org/10.1016/j.jdermsci.2012.07.007.CrossRefPubMed

30.

Assaf C, Hwang ST. Mac attack: macrophages as key drivers of cutaneous T-cell lymphoma pathogenesis. Exp Dermatol. 2016;25(2):105–6. https://doi.org/10.1111/exd.12894.CrossRefPubMed

31.

Tada K, Hamada T, Asagoe K, Umemura H, Mizuno-Ikeda K, Aoyama Y, et al. Increase of DC-LAMP+ mature dendritic cell subsets in dermatopathic lymphadenitis of mycosis fungoides. Eur J Dermatol. 2014;24(6):670–5. https://doi.org/10.1684/ejd.2014.2437.CrossRefPubMed

32.

Pizzi M, Margolskee E, Inghirami G. Pathogenesis of peripheral T cell lymphoma. Annu Rev Pathol. 2018;13:293–320. https://doi.org/10.1146/annurev-pathol-020117-043821.CrossRefPubMed

33.

Fox CP, Shannon-Lowe C, Gothard P, Kishore B, Neilson J, O’Connor N, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis. 2010;51(1):66–9. https://doi.org/10.1086/653424.CrossRefPubMed

34.

Shannon-Lowe C, Rickinson AB, Bell AI. Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond Ser B Biol Sci. 2017;372(1732):20160271. https://doi.org/10.1098/rstb.2016.0271.CrossRef

35.

Tan GW, Visser L, Tan LP, van den Berg A, Diepstra A. The microenvironment in Epstein-Barr virus-associated malignancies. Pathogens. 2018;7(2). https://doi.org/10.3390/pathogens7020040.

36.

van Beek J, zur Hausen A, Snel SN, Berkhof J, Kranenbarg EK, van de Velde CJ, et al. Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol. 2006;30(1):59–65.CrossRefPubMed

37.

Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d’Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin’s lymphoma. Haematologica. 2011;96(2):269–76. https://doi.org/10.3324/haematol.2010.031542.CrossRefPubMed

38.

Barros MH, Hassan R, Niedobitek G. Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res. 2012;18(14):3762–71. https://doi.org/10.1158/1078-0432.ccr-12-0129.CrossRefPubMed

39.

Barros MH, Segges P, Vera-Lozada G, Hassan R, Niedobitek G. Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival. PLoS One. 2015;10(5):e0124531. https://doi.org/10.1371/journal.pone.0124531.CrossRefPubMedPubMedCentral

40.

Kim YR, Kim SJ, Cheong JW, Chung H, Jang JE, Kim Y, et al. Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. Oncotarget. 2017;8(54):92312–23. https://doi.org/10.18632/oncotarget.21251.CrossRefPubMedPubMedCentral

41.

Chuang HC, Lay JD, Hsieh WC, Wang HC, Chang Y, Chuang SE, et al. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood. 2005;106(9):3090–6. https://doi.org/10.1182/blood-2005-04-1406.CrossRefPubMed

42.

• Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378(20):1947–8. https://doi.org/10.1056/NEJMc1803181 In this letter, Ratner and colleagues report the unfortunate experience of anti-PD1 for ATLL: the drug had probably an activating role on the lymphoma cells. The trial was closed after only three patients enrolled.CrossRefPubMed

43.

Wartewig T, Kurgyis Z, Keppler S, Pechloff K, Hameister E, Ollinger R, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552(7683):121–5. https://doi.org/10.1038/nature24649.CrossRefPubMedPubMedCentral

44.

Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, et al. Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888–98. https://doi.org/10.1182/blood-2017-08-802470.CrossRefPubMedPubMedCentral

45.

Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101(11):4267–72. https://doi.org/10.1182/blood-2002-09-2802.CrossRefPubMed

46.

Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98(6):1721–6.CrossRefPubMed

47.

Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, et al. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 2010;149(6):907–10. https://doi.org/10.1111/j.1365-2141.2010.08134.x.CrossRefPubMed

48.

Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, et al. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. 2013;119(12):2258–67. https://doi.org/10.1002/cncr.27972.CrossRefPubMed

49.

Sharma K, Janik JE, O'Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, et al. Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma. Clin Cancer Res : an official journal of the American Association for Cancer Research. 2017;23(1):35–42. https://doi.org/10.1158/1078-0432.ccr-16-1022.CrossRef

50.

• Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6. https://doi.org/10.1200/jco.2011.38.0402 Provides the first evidence of the activity of the monoclonal antibody immunoconjugate brentuximab vedotin in patients with relapsed/refractory ALCL.CrossRefPubMed

51.

Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–100. https://doi.org/10.1182/blood-2013-12-542142.CrossRefPubMedPubMedCentral

52.

Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–66. https://doi.org/10.1016/s0140-6736(17)31266-7.CrossRefPubMed

53.

Horwitz SM, Scarisbrick JJ, Dummer R, Duvic M, Kim YH, Walewski J, et al. Updated analyses of the international, open-label, randomized, phase 3 Alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). Blood. 2017;130(Suppl 1):1509.

54.

Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591–8. https://doi.org/10.1200/jco.2009.25.3575.CrossRefPubMed

55.

Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157–63. https://doi.org/10.1200/jco.2013.52.0924.CrossRefPubMed

56.

Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10(16):5494–500. https://doi.org/10.1158/1078-0432.ccr-04-0371.CrossRefPubMed

57.

Al-Zahrani M, Savage KJ. Peripheral T-cell lymphoma, not otherwise specified: a review of current disease understanding and therapeutic approaches. Hematol Oncol Clin North Am. 2017;31(2):189–207. https://doi.org/10.1016/j.hoc.2016.11.009.CrossRefPubMed

58.

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): results from the phase III MAVORIC study. Blood. 2017;130(Suppl 1):817.

59.

Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131(9):995–9. https://doi.org/10.1182/blood-2017-07-794214.CrossRefPubMedPubMedCentral

60.

Hari P, Raj RV, Olteanu H. Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma. N Engl J Med. 2016;375(15):1501–2. https://doi.org/10.1056/NEJMc1605684.CrossRefPubMed

61.

Horwitz SM, Hamadani M, Fanale MA, Feingold J, Spira AI, Fields PA, et al. Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma. Blood. 2017;130(Suppl 1):1510.

62.

Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018;11(1):15. https://doi.org/10.1186/s13045-018-0559-7.CrossRefPubMedPubMedCentral

63.

• Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437–42. https://doi.org/10.1182/blood-2016-12-756841 In this publication, Kwong and colleagues report the positive experience (100% ORR) of PD1 blockade in relapsed/refractory NKTL nasal type.CrossRefPubMed

64.

Chan TSY, Li J, Loong F, Khong PL, Tse E, Kwong YL. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety. Ann Hematol. 2018;97(1):193–6. https://doi.org/10.1007/s00277-017-3127-2.CrossRefPubMed

65.

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–704. https://doi.org/10.1200/jco.2015.65.9789.CrossRefPubMedPubMedCentral

66.

Khodadoust M, Rook AH, Porcu P, Foss FM, Moskowitz AJ, Shustov AR, et al. Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a Citn multicenter phase 2 study. Blood. 2016;128(22):181.

67.

Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35. https://doi.org/10.1182/blood-2009-08-239186.CrossRefPubMedPubMedCentral

68.

Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345(8941):9–13.CrossRefPubMed

69.

Morales O, Mrizak D, Francois V, Mustapha R, Miroux C, Depil S, et al. Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients. Br J Haematol. 2014;166(6):875–90. https://doi.org/10.1111/bjh.12980.CrossRefPubMed

70.

Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32(8):798–808. https://doi.org/10.1200/jco.2013.51.5304.CrossRefPubMed

71.

Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620–30. https://doi.org/10.1182/blood-2006-11-059139.CrossRefPubMedPubMedCentral

72.

Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113(25):6392–402. https://doi.org/10.1182/blood-2009-03-209650.CrossRefPubMedPubMedCentral

73.

Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126(8):983–92. https://doi.org/10.1182/blood-2015-02-629527.CrossRefPubMedPubMedCentral

74.

Chen KH, Wada M, Firor AE, Pinz KG, Jares A, Liu H, et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget. 2016;7(35):56219–32. https://doi.org/10.18632/oncotarget.11019.CrossRefPubMedPubMedCentral

75.

Pinz K, Liu H, Golightly M, Jares A, Lan F, Zieve GW, et al. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia. 2016;30(3):701–7. https://doi.org/10.1038/leu.2015.311.CrossRefPubMed

76.

Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, et al. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Am J Hematol. 2017;92(9):892–901. https://doi.org/10.1002/ajh.24794.CrossRefPubMedPubMedCentral

77.

Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285–96. https://doi.org/10.1182/blood-2017-01-761320.CrossRefPubMedPubMedCentral

78.

Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, et al. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018;32:1970–83. https://doi.org/10.1038/s41375-018-0065-5.CrossRefPubMedPubMedCentral

79.

Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, et al. Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017;23(12):1416–23. https://doi.org/10.1038/nm.4444.CrossRefPubMed

80.

Langerak AW, van Den Beemd R, Wolvers-Tettero IL, Boor PP, van Lochem EG, Hooijkaas H, et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood. 2001;98(1):165–73.CrossRefPubMed

81.

Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. The J Clin Investig. 2017;127(9):3462–71. https://doi.org/10.1172/jci94306.CrossRefPubMed

82.

Wu J, Fu J, Zhang M, Liu D. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015;8:96. https://doi.org/10.1186/s13045-015-0188-3.CrossRefPubMedPubMedCentral

83.

Ansell SM, Chen RW, Forero-Torres A, Armand P, Lossos IS, Reeder CB, et al. A phase 1 study investigating the combination of AFM13 and the monoclonal anti-PD-1 antibody pembrolizumab in patients with relapsed/refractory Hodgkin lymphoma after brentuximab vedotin failure: data from the dose escalation part of the study. Blood. 2017;130(Suppl 1):1522.

84.

Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood. 2012;119(2):355–63. https://doi.org/10.1182/blood-2011-05-355222.CrossRefPubMedPubMedCentral

85.

Maier T, Tun-Kyi A, Tassis A, Jungius KP, Burg G, Dummer R, et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood. 2003;102(7):2338–44. https://doi.org/10.1182/blood-2002-08-2455.CrossRefPubMed

86.

Bourlon C, Lacayo-Lenero D, Inclan-Alarcon SI, Demichelis-Gomez R. Hematopoietic stem cell transplantation for adult Philadelphia-negative acute lymphoblastic leukemia in the first complete remission in the era of minimal residual disease. Curr Oncol Rep. 2018;20(4):36. https://doi.org/10.1007/s11912-018-0679-9.CrossRefPubMed

87.

Cudillo L, Cerretti R, Picardi A, Mariotti B, De Angelis G, Cantonetti M, et al. Allogeneic hematopoietic stem cell transplantation in primary cutaneous T cell lymphoma. Ann Hematol. 2018;97(6):1041–8. https://doi.org/10.1007/s00277-018-3275-z.CrossRefPubMed

88.

Li C, Yang D, Chen J, Wang P, Zhang Y, Wu D. Outcome of allogeneic stem cell transplantation in T cell lymphoblastic lymphoma. Blood. 2017;130(Suppl 1):5535.

89.

Mehta-Shah N, Teja S, Tao Y, Cashen AF, Beaven A, Alpdogan O, et al. Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis. Blood. 2017;130(Suppl 1):4597.

90.

Inamoto Y, Fefer A, Sandmaier BM, Gooley TA, Warren EH, Petersdorf SH, et al. A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(9):1308–15. https://doi.org/10.1016/j.bbmt.2011.01.004.CrossRefPubMedPubMedCentral

91.

Miyamoto T, Fukuda T, Nakashima M, Henzan T, Kusakabe S, Kobayashi N, et al. Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan Marrow Donor Program. Biol Blood Marrow Transplant. 2017;23(6):938–44. https://doi.org/10.1016/j.bbmt.2017.02.012.CrossRefPubMed

92.

Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87(6):2195–204.PubMed

93.

Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041–50.PubMed

94.

Zhao Y, Su H, Shen X, Du J, Zhang X, Zhao Y. The immunological function of CD52 and its targeting in organ transplantation. Inflamm Res. 2017;66(7):571–8. https://doi.org/10.1007/s00011-017-1032-8.CrossRefPubMed

95.

Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One. 2012;7(6):e39416. https://doi.org/10.1371/journal.pone.0039416.CrossRefPubMedPubMedCentral

96.

Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51(1):25–34. https://doi.org/10.1053/j.seminhematol.2013.11.001.CrossRefPubMed

97.

Ishida T, Utsunomiya A, Jo T, Yamamoto K, Kato K, Yoshida S, et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies. Cancer Sci. 2017;108(10):2022–9. https://doi.org/10.1111/cas.13343.CrossRefPubMedPubMedCentral

98.

Asano N, Suzuki R, Ohshima K, Kagami Y, Ishida F, Yoshino T, et al. Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. Int J Hematol. 2010;91(3):426–35. https://doi.org/10.1007/s12185-010-0513-0.CrossRefPubMed

99.

Capriotti E, Vonderheid EC, Thoburn CJ, Bright EC, Hess AD. Chemokine receptor expression by leukemic T cells of cutaneous T-cell lymphoma: clinical and histopathological correlations. J Invest Dermatol. 2007;127(12):2882–92. https://doi.org/10.1038/sj.jid.5700916.CrossRefPubMed

100.

Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625–34.PubMed

101.

Tobinai K, Uike N, Saburi Y, Chou T, Etoh T, Masuda M, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int J Hematol. 2003;77(5):512–7.CrossRefPubMed

102.

Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77(2):164–70.CrossRefPubMed

103.

Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N, et al. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer. 1993;71(12):3888–95.CrossRefPubMed

104.

Wang L, Wang H, Li PF, Lu Y, Xia ZJ, Huang HQ, et al. CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type. Ann Hematol. 2015;94(8):1381–8. https://doi.org/10.1007/s00277-015-2359-2.CrossRefPubMed

105.

Mustafa N, Nee HFA, Lee XTJ, Jin W, Yu Y, Chen Y, et al. Daratumumab efficiently targets NK/T cell lymphoma with high CD38 expression. Blood. 2017;130(Suppl 1):2814.

106.

Triplett TA, Curti BD, Bonafede PR, Miller WL, Walker EB, Weinberg AD. Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG. Eur J Immunol. 2012;42(7):1893–905. https://doi.org/10.1002/eji.201242444.CrossRefPubMed

107.

Dhandha MM, Sufficool KE, Vidal CI, Robbins KJ, Fesler MJ, Batanian JR, et al. Immunophenotype expression change from CD52+ to CD52- on erythrodermic peripheral T-cell lymphoma, not otherwise specified after treatment with alemtuzumab. Am J Dermatopathol. 2018;40(7):547–50. https://doi.org/10.1097/dad.0000000000001000.CrossRefPubMed

108.

Tuset E, Matutes E, Brito-Babapulle V, Morilla R, Catovsky D. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia. Leuk Lymphoma. 2001;42(6):1379–83. https://doi.org/10.3109/10428190109097766.CrossRefPubMed

109.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331.CrossRefPubMed

110.

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. https://doi.org/10.1038/nrc3239.CrossRefPubMedPubMedCentral

111.

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMoa1003466.CrossRefPubMed

112.

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. The N Engl J Med. 2015;372(4):320–30. https://doi.org/10.1056/NEJMoa1412082.CrossRefPubMed

113.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35. https://doi.org/10.1056/NEJMoa1709030.CrossRefPubMed

114.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29. https://doi.org/10.1056/NEJMoa1709937.CrossRefPubMed

115.

Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–32. https://doi.org/10.1200/jco.2016.72.1316.CrossRefPubMedPubMedCentral

116.

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9. https://doi.org/10.1056/NEJMoa1411087.CrossRefPubMed

117.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–94. https://doi.org/10.1016/s1470-2045(16)30167-x.CrossRefPubMedPubMedCentral

118.

Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39. https://doi.org/10.1016/j.intimp.2018.06.001.CrossRefPubMed

119.

Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI, Dong H, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114(10):2149–58. https://doi.org/10.1182/blood-2009-04-216671.CrossRefPubMedPubMedCentral

120.

Phillips T, Devata S, Wilcox RA. Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. J Immunother Cancer. 2016;4, 95. https://doi.org/10.1186/s40425-016-0201-6.

121.

Merryman RW, Armand P. Immune checkpoint blockade and hematopoietic stem cell transplant. Curr Hematol Malig Rep. 2017;12(1):44–50. https://doi.org/10.1007/s11899-017-0362-5.CrossRefPubMed

122.

Ruella M, June CH. Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. Curr Hematol Malig Rep. 2016;11(5):368–84. https://doi.org/10.1007/s11899-016-0336-z.CrossRefPubMed

123.

Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. The N Engl J Med. 2010;362(10):875–85. https://doi.org/10.1056/NEJMoa0905680.CrossRefPubMed

124.

Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32:25–50. https://doi.org/10.1146/annurev-immunol-032713-120142.CrossRefPubMed

125.

Lin GHY, Chai V, Lee V, Dodge K, Truong T, Wong M, et al. TTI-621 (SIRPalphaFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLoS One. 2017;12(10):e0187262. https://doi.org/10.1371/journal.pone.0187262.CrossRefPubMedPubMedCentral

126.

Ansell S, Chen RW, Flinn IW, Maris MB, Connor OA, Johnson LDS, et al. A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies. Blood. 2016;128(22):1812.

127.

Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome—update 2017. Eur J Cancer. 2017;77:57–74. https://doi.org/10.1016/j.ejca.2017.02.027.CrossRefPubMed

128.

Bunn PA Jr, Foon KA, Ihde DC, Longo DL, Eddy J, Winkler CF, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med. 1984;101(4):484–7.CrossRefPubMed

129.

Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol. 1991;24(2 Pt 1):247–52.CrossRefPubMed

130.

Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9(5):1089–107.CrossRefPubMed

131.

Gramatzki M, Burger R, Strobel G, Trautmann U, Bartram CR, Helm G, et al. Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2 responsiveness. Leukemia. 1995;9(3):382–90.PubMed

132.

O’Mahony D, Morris JC, Stetler-Stevenson M, Matthews H, Brown MR, Fleisher T, et al. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res : an official journal of the American Association for Cancer Research. 2009;15(7):2514–22. https://doi.org/10.1158/1078-0432.ccr-08-1254.CrossRef

Title: Novel Immunotherapies for T Cell Lymphoma and Leukemia
Authors: Paola Ghione
Alison J. Moskowitz
Nadia E. K. De Paola
Steven M. Horwitz
Marco Ruella
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Hematologic Malignancy Reports / Issue 6/2018
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-018-0480-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Novel Immunotherapies for T Cell Lymphoma and Leukemia

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 6/2018

Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry

Online and Social Media Resources for Patients with MDS

Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria

Chronic Myeloid Leukemia: Beyond BCR-ABL1

Leveraging Hypomethylating Agents for Better MDS Therapy

Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page